Pharma in silica's mission is to improve the cancer patient outcomes with high-innocuity chemotherapy solutions. The preclinical-stage, Québec City-based, nimble and intangible-asset company intends to file an IND by the end of 2021.

in silica™ is a proprietary transport and liberation technology. Its functionalized and porous silica spheres promise distinctive advantages over established nanomedicine technologies (clean formulation, reduced exposure, improved on-target rate, efficient TME and in-tumour liberation).

Pharma in silica

The in silica drug carrier

patient-injection

The versatility of silica’s chemistry is likely to grant the in silica™ drug carrier distinctive advantages over established nanomedicines such as liposomes and protein-linked drugs.

A silica sphere can be engineered for single or multiple-drug administration, optimal nano or micro size, simple and safe formulation, leakage-free and long-duration circulation, high-tumour selectivity and environment-triggered, tuneable release. Each vehicle is designed to suit the drug cargo and the cancer it treats. The resulting solution is scalable under GMP, cost-effective and patentable.

Pharma in silica currently develops safer versions of off-patent chemotherapy agents such as paclitaxel and docetaxel for NSCLC. Other development opportunities will be pursued via out-licensing, partnering and project-specific financing.

A novel and proprietary drug carrier

  • Sophisticated chemistry.
  • Clean synthesis.
  • Scalable.
  • Cost-effective.
  • GLP/GMP compatible.
  • Proprietary.
in silica microsphere

Pharma in silica

Email: arcandf@pharma-insilica.com

Phone: (+1) 418.874.0054 #233

Fax: (+1) 418.874.0355

Francois Arcand, Pharma in silica's president
Francois Arcand, Pharma in silica's president